Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Delingpole: Churchill Was Racist? Wait Till They Hear About Who He Beat
08:46am, Tuesday, 09'th Jun 2020
Part of the problem is that the police -- or at least their right-on superiors -- no longer see it as their job to combat actual crime.
Ascendis Pharma A/S Announces Participation in ENDO Online 2020
12:15pm, Monday, 08'th Jun 2020
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations related to its rare disease end
Should You Avoid Ascendis Pharma A/S (ASND)?
07:46pm, Wednesday, 03'rd Jun 2020
In this article we will check out the progression of hedge fund sentiment towards Ascendis Pharma A/S (NASDAQ:ASND) and determine whether it is a good investment right now. We at Insider Monkey like t
Travis Scott Nike Air Max 270 Cactus Trails Store List | SneakerNews.com
08:30pm, Friday, 22'nd May 2020
Travis Scott‘s Nike collaborations have always had one thing in common: they’re all pure reflections of the artist’s own personal style. And while at first not as overt or as well-defined, the r
Earnings Beat: Ascendis Pharma A/S (NASDAQ:ASND) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
10:14am, Friday, 22'nd May 2020
Investors in Ascendis Pharma A/S (NASDAQ:ASND) had a good week, as its shares rose 5.0% to close at US$147 following...
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
12:00am, Thursday, 21'st May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs on May 20.)
ADC Therapeutics SA (...
Ascendis Pharma A/S Reports First Quarter 2020 Financial Results
08:01pm, Tuesday, 19'th May 2020
– On track for filing U.S. Biologics License Application for TransCon hGH in second quarter, and advancing Marketing Authorisation Application in Europe to third quarter – –.
Ascendis Pharma A/S to Host Earnings Call
06:30pm, Tuesday, 19'th May 2020
NEW YORK, NY / ACCESSWIRE / May 19, 2020 / Ascendis Pharma A/S (NASDAQ:ASND) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 19, 2020 at 4:30 PM E
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 18)
ADC Therapeutics SA (NYSE:...
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows
12:00am, Sunday, 17'th May 2020
Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available online ...
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
12:00am, Wednesday, 13'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer
12:30pm, Monday, 11'th May 2020
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will appoint Jesper Høil
7 “Strong Buy” Healthcare Stocks to Buy Now
03:46pm, Friday, 08'th May 2020
As the month of May kicked off, stocks got off to a rocky start. The market slumped in response to a first quarter profit miss from eCommerce giant Amazon (NASDAQ:AMZN) and its plan to put all second-
Ascendis Pharma A/S Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 19
08:01pm, Thursday, 07'th May 2020
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference ca
BioMarin Pharmaceutical (BMRN) Receives a Buy from Canaccord Genuity
10:12am, Friday, 01'st May 2020
In a report issued on April 27, Michelle Gilson from Canaccord Genuity maintained a Buy rating on BioMarin Pharmaceutical (BMRN), with a price target of
